Responses
Clinical and epidemiological research
Extended report
Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials
Compose a Response to This Article
Other responses
No responses have been published for this article.